Natco Pharma Approves Demerger of Agrochemicals Business, New Nigeria Subsidiary
Natco Pharma approved a demerger of its Agrochemicals business into Natco Crop Health Sciences Limited, with an appointed date of October 1, 2026. The company will also invest up to USD 100,000 (approx. ₹83 lakh) in a new Nigeria subsidiary and plans to liquidate its Australian subsidiary by September 2026.
The demerger of a business vertical and the proposed listing of the resulting entity are significant corporate actions that can impact the company's structure, operations, and shareholder value.
The approval of a demerger to unlock value and focused growth, along with the establishment of a new subsidiary in Nigeria, are positive developments for the company.
Natco Pharma Limited's Board of Directors has approved a Scheme of Arrangement for the demerger of its Agrochemicals Business into a wholly-owned subsidiary, Natco Crop Health Sciences Limited. The appointed date for this demerger is October 1, 2026. The scheme involves issuing one equity share of the Resulting Company for every one equity share held in the Demerged Company. The Agrochemicals division had a turnover of ₹60.62 crore as of March 31, 2025, representing 1.48% of the company's total turnover.
The demerger aims to achieve focused growth, operational efficiencies, and unlock value for shareholders by segregating the distinct business verticals. The Resulting Company is proposed to be listed on the BSE and NSE.
Additionally, the Board approved the incorporation of a wholly-owned subsidiary in Nigeria, NATCO Pharma Nigeria Limited, with an investment not exceeding USD 100,000 (approximately ₹83 lakh). The company also decided to liquidate its wholly-owned subsidiary in Australia, M/s. Natco Pharma Australia Pty Ltd., by the end of September 2026, due to a change in business model and to avoid administrative costs.
The board meeting commenced at 2:45 PM and concluded at 4:10 PM on March 24, 2026.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under demerger. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.